PT-141 Dosage

What is PT-141, and how does it work?

PT-141, also known as bremelanotide, is a synthetic peptide that the Vyleesi label describes as a melanocortin receptor agonist with activity at the MC4R subtype (Vyleesi Prescribing Information).

It is a synthetic analog of alpha-melanocyte-stimulating hormone. The label notes it activates several melanocortin receptor subtypes, with MC1R and MC4R most relevant at studied dose levels, and adds that the exact mechanism behind its studied effects is not fully established (Vyleesi Prescribing Information). The label's stated indication is for hypoactive sexual desire disorder (HSDD) in premenopausal adults, a persistent lack of sexual desire that causes marked distress (Vyleesi Prescribing Information). Research-grade PT-141 is a separate, non-prescription material and is not that approved product.

What PT-141 dosage did the RECONNECT trials report?

The RECONNECT phase 3 program studied a single fixed dose of 1.75 mg bremelanotide given by subcutaneous injection, taken as needed (Kingsberg et al., 2019).

RECONNECT was two phase 3 randomized controlled trials, both testing bremelanotide 1.75 mg subcutaneous, self-administered as needed, against placebo over a 24-week core phase (Kingsberg et al., 2019). The trials did not titrate the dose up or down: the 1.75 mg amount was fixed for everyone in the active arm. That single-dose design is why most PT-141 dosage discussion centers on one number rather than a range.

Research-reported PT-141 dosing parameters

These figures describe what the trials and the label report for a controlled study population. They are not a recommendation, a starting point, or a target for any individual.

How often was PT-141 used in the studies?

The Vyleesi label describes an on-demand pattern of no more than one dose in any 24-hour window and no more than 8 doses in a month (Vyleesi Prescribing Information).

PT-141 was not studied as a daily peptide. In the label's model, a dose is taken before anticipated activity, at least 45 minutes ahead, and only when wanted (Vyleesi Prescribing Information). The 8-dose monthly ceiling is not arbitrary: the label ties more frequent use to a risk of focal darkening of the skin, or hyperpigmentation (Vyleesi Prescribing Information). The label also notes that each dose can cause a short-lived rise in blood pressure and a small drop in heart rate for several hours (Vyleesi Prescribing Information).

What side effects did PT-141 research report?

Nausea was the most commonly reported side effect in the phase 3 program, seen in about 40 percent of the bremelanotide group versus about 1 percent on placebo (Kingsberg et al., 2019).

Beyond nausea, the phase 3 trials and the label report flushing, injection site reactions, headache, and vomiting among common adverse reactions, with flushing near 20 percent and headache near 11 percent in the active arm (Kingsberg et al., 2019; Vyleesi Prescribing Information). It also flags transient blood pressure increases after dosing and warns against use in people with uncontrolled high blood pressure or known cardiovascular disease (Vyleesi Prescribing Information). These are label facts about the approved product, not predictions about any research use.

Why is PT-141 dosage framed as research-reported instead of a recommendation?

The 1.75 mg figure describes a controlled trial population and an approved product, not you, so only a qualified clinician can translate it into a personal decision.

The RECONNECT dose was set for a specific studied group under medical supervision (Kingsberg et al., 2019). Body weight, health conditions, other medications, and the reasons behind the label's blood pressure and hyperpigmentation warnings all change how a number like 1.75 mg should be read (Vyleesi Prescribing Information). That translation is a clinician's job, not a web page's.

How does the as-needed model compare to daily peptides?

PT-141 was studied as a single on-demand injection before anticipated activity, unlike peptides studied on fixed daily schedules (Kingsberg et al., 2019).

Many research peptides are studied with a steady daily or near-daily rhythm to hold levels stable. PT-141 is different: the RECONNECT design and the label both describe a one-off dose taken only when wanted, with strict per-day and per-month caps (Kingsberg et al., 2019; Vyleesi Prescribing Information). Total exposure therefore depends on how often it is used, which is the reason the monthly ceiling exists.